What to know first
Compounded semaglutide and tirzepatide are the same active molecules as Wegovy, Ozempic and Zepbound, but mixed by 503A pharmacies under prescription rather than manufactured under FDA new-drug approval. The cash-pay savings are real but the regulatory environment is fluid. The FDA declared the semaglutide shortage resolved in February 2025; Lilly has filed coordinated lawsuits against compounded tirzepatide pharmacies. Programs that still offer compounded are operating under clear enforcement risk.
What we considered
- Pharmacy partner stability (recent enforcement history?)
- Transparency on sourcing and regulatory exposure
- Plan B if compounded supply is cut off mid-treatment
- Pricing relative to branded direct-to-consumer (NovoCare, LillyDirect)
Some visit links earn us a commission.
Scores out of 10, equal-weighted across five dimensions. How we score
Top pick: Mochi Health
Mochi's flat-priced compounded program is the most transparent in the category about sourcing, pharmacy partners and regulatory risk. They have publicly addressed pharmacy shutdowns and what their continuity plan is.
Read the full Mochi Health review →
Other strong picks
Related
